GlassScriptPhysician profile
Kristy D Carroll
NPI 1609960343
$3,274.92
in general payments reported to CMS, 2019-2025
27 companies · $754 in 2025
The $754 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $674 · 2022: $424 · 2023: $433 · 2024: $991 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152 · Education: $25.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.55 |
| Education | $25.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $851.35 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $548.52 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $381.32 | 2021 | |
| Novo Nordisk INC | $298.34 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $270.04 | 2023-2025 | |
| Lilly USA, LLC | $239.43 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $86.57 | 2023-2024 | Trintellix |
| Amgen INC. | $80.46 | 2022-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $62.30 | 2023-2025 | Veozah |
| Paratek Pharmaceuticals, INC. | $60.33 | 2022-2024 | Nuzyra |
| Amarin Pharma, INC. | $57.43 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.38 | 2022 | |
| Supernus Pharmaceuticals, INC. | $33.87 | 2022 | |
| Corcept Therapeutics | $31.13 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $30.45 | 2025 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.42 | 2024 | Proclaim |
| Axsome Therapeutics, INC. | $22.97 | 2025 | Auvelity |
| Scilex Pharmaceuticals INC. | $20.69 | 2021 | |
| Neurocrine Biosciences, INC. | $20.64 | 2025 | |
| Phathom Pharmaceuticals, INC. | $19.00 | 2024 | Voquezna |
| Sk Life Science, INC. | $18.92 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.62 | 2021 | |
| Scynexis, INC. | $15.95 | 2022 | |
| Viatris Specialty LLC | $15.01 | 2025 | Yupelri |
| Medtronic, INC. | $14.40 | 2022 | |
| Glaxosmithkline, LLC. | $13.20 | 2023 | Trelegy Ellipta |
| Genentech USA, INC. | $6.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristy Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.